Pancreatic Cancer Awareness Month

Study data show that no patient with a response required opioids after a 24-hour post-procedure follow-up.

The updated Prescription Drug User Fee Act date for zenocutuzumab in these indications is February 4, 2025.

The 18-month overall survival rate with the mitazalimab combination in OPTIMIZE-1 exceeds a historical rate achieved with FOLFIRINOX alone.

Tanios S. Bekaii-Saab, MD, emphasizes the idea of moving targeted therapies to earlier lines of treatment to further improve outcomes in pancreatic cancer.

It may be crucial to test every patient for markers such as BRAF V600E mutations, NRG1 fusions, and KRAS G12C mutations to help manage pancreatic cancers.

Increasing patient awareness of modifiable risk factors for pancreatic cancer may help mitigate incidence of pancreatic cancers.

Differences in pancreatic cancer responses to treatment elicits a need to better educate patients on expectations in treatment, particularly chemotherapy.

The incorporation of palliative care specific to mental health services and therapy remains underutilized in the care of patients with pancreatic cancer.

Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.

Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.

An advanced computation linguistics model that can detect pancreatic cysts can help patients prevent pancreatic tumors from forming.

Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

A computational linguistics model has mitigated disparities in surveillance of the pancreas that primarily affected racial and ethnic minorities.

A computational linguistics model designed to locate pancreatic cysts that started to locate pancreatic cancer has the potential to lead to more efficient treatment.

Shubham Pant, MD, MBBS, highlights an “exciting time” in the treatment of patients with RAS-mutated pancreatic cancer.

Medical use of AI increases every day, and in the future, will be exponentially greater and many forms of treatment will be improved, according to Russell C. Langan, MD, FACS, FSSO.

Shubham Pant, MD, MBBS, highlights how pan-RAS inhibitors, RAS-directed vaccines, and biomarker testing can improve outcomes in pancreatic cancer.

Bolstering the effectiveness of T cells and the further implementation of AI can both yield positive results in the future of pancreatic cancer treatment.

The key to the future of pancreatic cancer treatment is immunotherapy, according to Gregory L. Beatty, MD, PhD.

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

The development of RAS-directed vaccines may help decrease the likelihood of disease recurrence in patients undergoing treatment for pancreatic cancer.

Only a few groups of patients get screened for pancreatic cancer, those with a genetic risk or pancreatic cysts among them, which can increase lethality for unidentified populations.

Tumor treating fields with chemotherapy improved overall survival for patients with unresectable, locally advanced pancreatic adenocarcinoma.

The pancreatic cancer field may not be far from seeing the use of non-invasive blood tests in pancreatic cancer, said Ajay Goel, PhD, AGAF.

There are certain markers that can point to a greater risk of pancreatic cancer like BRCA1/2, and diabetes, according to Brian M. Wolpin, MD.

The relatively inexpensive nature of liquid biopsy may allow for more frequent screening among individuals who are at risk of developing pancreatic cancer.

The rare nature of pancreatic cancer makes identifying it difficult, but progress towards earlier identification is being made, according to Brian M. Wolpin, MD, MPH.

In an era where medical records are digitalized, artificial intelligence has the potential to identify patterns that can locate at-risk patients with pancreatic cancer.

An artificial intelligence model may help move patients into treatment pathways for pancreatic cancer quicker, says Russell C. Langan, MD, FACS, FSSO.

AI may open pathways to locate pancreatic cancer earlier and in higher-risk patient subgroups, according to Debiao Li, PhD, and Stephen Pandol, MD.

Gemcitabine plus capecitabine was found to elicit longer survival outcomes than capecitabine alone in patients with pancreatic adenocarcinoma.

No dose-limiting toxicities were observed with upamostat combination therapy in patients with metastatic pancreatic cancer.

Investigators of a phase 2a trial plan to include additional combination arms assessing treatment with IMM-1-104 across different patient populations.

Investigators are assessing treatment with ELC-100 among patients with pancreatic neuroendocrine tumors as part of a phase 1/2 trial.

Results from the phase 3 LAPIS trial showed pamrevlumab/chemotherapy did not improve survival vs placebo/chemotherapy in locally advanced, unresectable pancreatic cancer.

The phase 2 EA2186 trial was the first elderly-specific clinical trial evaluating chemotherapy in vulnerable adults with metastatic pancreatic cancer.

A 3-cohort retrospective analysis compared patients who met eligibility for the NAPOLI 3 trial with all-comers treated with FOLFIRINOX for PDAC.

Cohort 5 of the ongoing phase 1/2 GOBLET study evaluated the safety of pelareorep in combination with modified FOLFIRINOX with or without atezolizumab in patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma.

Post hoc analysis of the phase 3 NAPOLI 3 trial assessed how dose reductions in liposomal irinotecan/oxaliplatin affect OS in NALIRIFOX-treated PDAC.